Trials / Completed
CompletedNCT00366171
Open Label Extension Study of Bifeprunox
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bifeprunox |
Timeline
- Start date
- 2006-11-01
- Completion
- 2007-10-01
- First posted
- 2006-08-21
- Last updated
- 2007-12-27
Locations
83 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00366171. Inclusion in this directory is not an endorsement.